FDA Releases Final Guidance on Investigating Devices for Benign Prostatic Hyperplasia Treatment

Summary

The Food and Drug Administration (FDA) has made available a final guidance document outlining the requirements for non-clinical and clinical investigations of devices intended to treat benign prostatic hyperplasia (BPH), which will aid in the review of device applications and submissions.